CN104203951B - 肝x受体调节剂 - Google Patents

肝x受体调节剂 Download PDF

Info

Publication number
CN104203951B
CN104203951B CN201380014354.5A CN201380014354A CN104203951B CN 104203951 B CN104203951 B CN 104203951B CN 201380014354 A CN201380014354 A CN 201380014354A CN 104203951 B CN104203951 B CN 104203951B
Authority
CN
China
Prior art keywords
disease
compound
mmol
mixture
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380014354.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104203951A (zh
Inventor
董成国
范怡
卡特琳娜·莱夫泰瑞斯
斯蒂芬·洛泰斯特
苏雷什·B·辛格
科林·泰斯
赵伟
郑亚军
庄凌航
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitae Pharmaceuticals LLC
Original Assignee
Vitae Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals LLC filed Critical Vitae Pharmaceuticals LLC
Publication of CN104203951A publication Critical patent/CN104203951A/zh
Application granted granted Critical
Publication of CN104203951B publication Critical patent/CN104203951B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN201380014354.5A 2012-03-16 2013-03-14 肝x受体调节剂 Expired - Fee Related CN104203951B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612051P 2012-03-16 2012-03-16
US61/612,051 2012-03-16
PCT/US2013/031242 WO2013138565A1 (en) 2012-03-16 2013-03-14 Liver x receptor modulators

Publications (2)

Publication Number Publication Date
CN104203951A CN104203951A (zh) 2014-12-10
CN104203951B true CN104203951B (zh) 2016-11-02

Family

ID=47997957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380014354.5A Expired - Fee Related CN104203951B (zh) 2012-03-16 2013-03-14 肝x受体调节剂

Country Status (27)

Country Link
US (4) US9006244B2 (enExample)
EP (1) EP2825541B1 (enExample)
JP (3) JP6114814B2 (enExample)
KR (1) KR102069912B1 (enExample)
CN (1) CN104203951B (enExample)
AU (1) AU2013232066B2 (enExample)
CA (1) CA2866218C (enExample)
CY (1) CY1118318T1 (enExample)
DK (1) DK2825541T3 (enExample)
EA (1) EA026907B1 (enExample)
ES (1) ES2598653T3 (enExample)
HR (1) HRP20161196T1 (enExample)
HU (1) HUE029402T2 (enExample)
IL (1) IL234265B (enExample)
IN (1) IN2014DN07636A (enExample)
LT (1) LT2825541T (enExample)
ME (1) ME02534B (enExample)
MX (1) MX354818B (enExample)
NZ (1) NZ629122A (enExample)
PL (1) PL2825541T3 (enExample)
PT (1) PT2825541T (enExample)
RS (1) RS55166B1 (enExample)
SG (1) SG11201405328SA (enExample)
SI (1) SI2825541T1 (enExample)
SM (1) SMT201600374B (enExample)
WO (1) WO2013138565A1 (enExample)
ZA (1) ZA201406326B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2825541B1 (en) * 2012-03-16 2016-06-22 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
BR112014022780A8 (pt) * 2012-03-16 2021-06-15 Vitae Pharmaceuticals Inc composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
WO2015195922A1 (en) * 2014-06-19 2015-12-23 Vitae Pharmaceuticals, Inc. Compounds for use in treating acute coronary syndrome and related conditions
MX377304B (es) * 2014-08-07 2025-03-07 Vitae Pharmaceuticals Llc Derivados de piperazina como moduladores de los receptores x del hígado.
US20190125745A1 (en) * 2014-12-17 2019-05-02 Rgenix, Inc. Treatment and diagnosis of cancer
CN105017262B (zh) * 2015-07-07 2017-05-03 广东也乐新材料制造有限公司 一种醛基取代多环杂芳烃化合物的合成方法
CN105288658B (zh) * 2015-10-30 2018-08-28 中国人民解放军第三军医大学 miR-18a-5p抑制剂在制备防治骨质疏松药物中的应用
CN109069461A (zh) 2016-01-11 2018-12-21 洛克菲勒大学 与髓源性抑制细胞相关的病症的治疗方法
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761073A1 (fr) * 1997-03-20 1998-09-25 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
CN101456863A (zh) * 2007-12-14 2009-06-17 华北制药集团新药研究开发有限责任公司 新的lxr激动剂及其制备方法和用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748247A (en) 1986-10-21 1988-05-31 American Home Products Corporation 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
EP0511993A1 (en) 1990-01-22 1992-11-11 E.I. Du Pont De Nemours And Company Herbicidal sulfonylureas
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
ATE456367T1 (de) 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
AU3831495A (en) 1994-10-20 1996-05-15 American Home Products Corporation Indole derivatives useful as serotonergic agents
EP0912175A4 (en) 1996-06-28 1999-09-08 Merck & Co Inc FIBRINOGENIC RECEPTOR ANTAGONISTS
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2257937A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
FR2761070B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
DE19802235A1 (de) 1998-01-22 1999-07-29 Bayer Ag Mit tricyclischen Indolen substituierte Oxazolidinone
ID23219A (id) 1998-04-17 2000-03-30 Lilly Co Eli Trisiklik tersubstitusi
CA2371472A1 (en) 1999-05-06 2000-11-16 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
WO2001030331A2 (en) 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
JP2003525874A (ja) 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
AU2001283955B2 (en) 2000-07-31 2006-05-18 F. Hoffmann-La Roche Ag Piperazine derivatives
WO2002059082A2 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
FR2829766A1 (fr) 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
BR0215288A (pt) 2001-12-21 2004-12-21 King Phamaceuticals Res & Dev Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
US7994196B2 (en) 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
CA2560311A1 (en) 2004-04-08 2005-10-20 Novartis Ag Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
WO2005113526A2 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
MX2007006896A (es) * 2004-12-15 2007-06-26 Hoffmann La Roche Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
CA2593266A1 (en) 2005-01-03 2006-07-13 Universita Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
SI1904477T1 (sl) 2005-07-14 2009-06-30 Hoffmann La Roche Derivati indol-3-karbonil-spiro-piperidina kot antagonisti V1A receptorja
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP2007137810A (ja) * 2005-11-17 2007-06-07 Sankyo Co Ltd インドール化合物を含有する医薬
ATE448230T1 (de) 2005-12-09 2009-11-15 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
TWI539947B (zh) 2007-04-09 2016-07-01 米希爾金尼公司 組蛋白去乙醯基酶之抑制劑
US20110002855A1 (en) 2007-06-25 2011-01-06 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
JP2011507901A (ja) * 2007-12-21 2011-03-10 ワイス・エルエルシー ピラゾロ［１，５−ａ］ピリミジン化合物
BRPI0907230A2 (pt) 2008-01-22 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto
US20090192147A1 (en) 2008-01-30 2009-07-30 Wyeth [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW201031665A (en) 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
ES2462290T3 (es) 2009-06-08 2014-05-22 Grünenthal GmbH Bencimidazoles, benzotiazoles y benzoxazoles sustituidos
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
CA2772522A1 (en) 2009-09-11 2011-03-17 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US9073926B2 (en) 2009-12-07 2015-07-07 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
US8654867B2 (en) * 2011-12-07 2014-02-18 Texas Instruments Incorporated Transformer power combiner with filter response
EP2825541B1 (en) * 2012-03-16 2016-06-22 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
BR112014022780A8 (pt) 2012-03-16 2021-06-15 Vitae Pharmaceuticals Inc composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761073A1 (fr) * 1997-03-20 1998-09-25 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
CN101456863A (zh) * 2007-12-14 2009-06-17 华北制药集团新药研究开发有限责任公司 新的lxr激动剂及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Streamlined access to 2,3-dihydropyrazino[1,2-a]indole-1,4-diones via Ugi reaction followed by microwave-assisted cyclization";Sergey Tsirulnikov等，;《Tetrahedron Letters》;20090722;第50卷;第5529-5531页 *
"海洋来源真菌A-f-11中吲哚二酮哌嗪类抗肿瘤活性成分的研究";赵文英等，;《中国抗生素杂志》;20061231;第31卷(第12期);第749-752，764页 *

Also Published As

Publication number Publication date
SI2825541T1 (sl) 2016-10-28
CA2866218A1 (en) 2013-09-19
US9814715B2 (en) 2017-11-14
US20150051214A1 (en) 2015-02-19
US20170136017A1 (en) 2017-05-18
CY1118318T1 (el) 2017-06-28
EA201491609A1 (ru) 2014-12-30
JP2017128588A (ja) 2017-07-27
IL234265B (en) 2020-06-30
KR102069912B1 (ko) 2020-01-23
MX354818B (es) 2018-03-21
CA2866218C (en) 2020-06-09
AU2013232066A1 (en) 2014-09-11
US9006245B2 (en) 2015-04-14
PL2825541T3 (pl) 2016-12-30
HUE029402T2 (en) 2017-02-28
EA026907B1 (ru) 2017-05-31
PT2825541T (pt) 2016-09-28
DK2825541T3 (en) 2016-10-03
NZ629122A (en) 2016-04-29
JP2019023196A (ja) 2019-02-14
US9006244B2 (en) 2015-04-14
IN2014DN07636A (enExample) 2015-05-15
CN104203951A (zh) 2014-12-10
SMT201600374B (it) 2016-11-10
RS55166B1 (sr) 2017-01-31
ME02534B (me) 2017-02-20
ZA201406326B (en) 2019-11-27
SG11201405328SA (en) 2014-11-27
LT2825541T (lt) 2016-12-27
HK1206333A1 (en) 2016-01-08
JP6114814B2 (ja) 2017-04-12
US20150080406A1 (en) 2015-03-19
EP2825541A1 (en) 2015-01-21
HRP20161196T1 (hr) 2016-11-04
KR20140139555A (ko) 2014-12-05
US9388190B2 (en) 2016-07-12
MX2014011103A (es) 2014-12-05
AU2013232066B2 (en) 2017-07-06
EP2825541B1 (en) 2016-06-22
ES2598653T3 (es) 2017-01-30
JP2015510892A (ja) 2015-04-13
US20150246924A1 (en) 2015-09-03
WO2013138565A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
CN104203951B (zh) 肝x受体调节剂
CN104203950B (zh) 肝x受体调节剂
CA3117449A1 (en) 5-membered heteroaryl carboxamide compounds for treatment of hbv
HK1206333B (en) Liver x receptor modulators
HK1206332B (en) Liver x receptor modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161102

CF01 Termination of patent right due to non-payment of annual fee